Analyst Price Targets — ESPR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| November 24, 2025 10:30 pm | — | Piper Sandler | $9.00 | $3.17 | TheFly | Esperion initiated with an Overweight at Piper Sandler |
| September 25, 2025 6:15 pm | Kristen Kluska | Cantor Fitzgerald | $9.00 | $2.56 | TheFly | Esperion price target raised to $9 from $7 at Cantor Fitzgerald |
| December 17, 2024 11:36 am | Kristen Kluska | Cantor Fitzgerald | $8.00 | $3.04 | TheFly | Esperion initiated with an Overweight at Cantor Fitzgerald |
| May 4, 2022 12:00 am | Serge Belanger | Needham | $12.00 | $6.53 | TipRanks Contributor | Esperion Therapeutics Rises on Upbeat Q1 Results |
| May 4, 2021 12:00 am | Derek Archila | Wells Fargo | $20.00 | $25.59 | Benzinga | Esperion Stock Plummets On Wider Than Expected Q1 Earnings Loss; Analysts Move To Sidelines |
Latest News for ESPR
Esperion Therapeutics (NASDAQ: ESPR) outlined its commercial progress and strategic priorities at Needham and Company's 25th Annual Healthcare Conference, highlighting revenue growth, new clinical and guideline tailwinds for its cholesterol franchise, and the recent acquisition of Corstasis Therapeutics and its heart failure product Enbumyst. President and CEO Sheldon Koenig said the company has made significant…
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock?
JPMorgan Chase and Co. raised its stake in Esperion Therapeutics, Inc. (NASDAQ: ESPR) by 68.4% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 945,491 shares of the biopharmaceutical company's stock after buying an additional 384,095 shares during the
NEW YORK and ANN ARBOR, Mich., April 02, 2026 (GLOBE NEWSWIRE) -- Athyrium Capital Management, LP and Esperion Therapeutics, Inc. (Nasdaq: ESPR) today announced the entry into a $50 million royalty financing agreement under which certain funds managed by Athyrium Capital Management (the “Athyrium Funds”) will acquire 100% of Esperion's royalty interest, held by Esperion pursuant to that certain License and…
– Enbumyst, First and Only FDA-Approved Nasal Spray Loop Diuretic Now Integrated into Esperion's Cardiovascular Franchise, Anticipated to Drive Portfolio Expansion, Commercial Leverage, and Continued Revenue Growth –
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ESPR.
U.S. House Trading
No House trades found for ESPR.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.